Important information regarding Vyzulta

Posted in Latest News on March 16, 2018.

During the March 9, 2018 Board of Optometry meeting, the board approved for addition to Rule 64B13-18.002 Formulary of Topical Ocular Pharmaceutical Agents, Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%.

Important note, Vyzulta, at this time, cannot be prescribed by licensed Optometrists in Florida until the rule has been approved. Once the rule has gone through the approval process, notice will be provided on this site, and at that time Vyzulta may be prescribed.



More Latest News

Important notice regarding Rhopressa
February 12, 2019

The board approved Rhopressa (netarsudil ophthalmic solution) 0.02% for addition to Rule 64B13-18.002. Effective January 25, 2019, Licensees are now permitted to prescribe Rhopressa. Continue reading


Florida Jurisprudence CE Requirement
February 11, 2019

The Board of Optometry voted to waive the 2-hour Florida Jurisprudence requirement for all out-of-state licensees for the current biennium only. Click Here for more information. Continue reading